Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib + Carboplatin + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT01653912Phase 2Completed
- Sponsor
- Accenture
- Start
- Nov 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in ovarian cancer, sponsored by Accenture. Primary endpoints: Number of Subjects With Treatment-Emergent Adverse Events of Grade Greater Than or Equal to 3, Number of Subjects Reporting Adverse Events and 2 more. Started Nov 2012; status: completed.
02
Drugs
afuresertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01653912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653912.